RELATED CONTENT
NEWS
- Merck Serono ditches cladribine, leaving MS franchise exposed
- Focus on Almirall: partnering, new products and mature markets are key targets
- Lupin seeds research accord with Medicis while settling Solodyn dispute
- Conditional European approval for Fampyra for MS walking disability

